Ensartinib Lowers Recurrence Risk in ALK-Positive NSCLC
Episode Summary
Daily ensartinib significantly prolonged disease-free survival after chemotherapy and complete resection of ALK-positive NSCLC, supporting biomarker-guided postoperative therapy while long-term survival and safety remain under evaluation.